165 related articles for article (PubMed ID: 26606912)
1. European Association for the Study of Diabetes 51st Annual Meeting.
Gao HX; Regier EE; Close KL
J Diabetes; 2016 Mar; 8(2):177-80. PubMed ID: 26606912
[No Abstract] [Full Text] [Related]
2. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
Bloomgarden ZT
J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
[No Abstract] [Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
Goldberg N; Fralick M
CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
[No Abstract] [Full Text] [Related]
4. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
Cherney DZ; Udell JA
Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
[No Abstract] [Full Text] [Related]
5. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin (Jardiance) for diabetes.
Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
[No Abstract] [Full Text] [Related]
7. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Bloomgarden Z
J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
[No Abstract] [Full Text] [Related]
8. Hot Topics in Primary Care: Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
Miller K; Miller EM
J Fam Pract; 2015 Dec; 64(12 Suppl):S54-8. PubMed ID: 26845015
[TBL] [Abstract][Full Text] [Related]
9. [Empagliflozin: another of silent revolutioners].
Kvapil M
Vnitr Lek; 2014 Nov; 60(11):924-5. PubMed ID: 25612346
[No Abstract] [Full Text] [Related]
10. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
11. EMPA-REG - the "diuretic hypothesis".
McMurray J
J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
[No Abstract] [Full Text] [Related]
12. SGLT2 inhibitors and renal function.
Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
[No Abstract] [Full Text] [Related]
13. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
Wang AY; Hou SK; Li SJ; Kao WF
Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
[No Abstract] [Full Text] [Related]
14. [Introduction].
García SD
Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
[No Abstract] [Full Text] [Related]
15. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Rajasekeran H; Lytvyn Y; Cherney DZ
Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
[TBL] [Abstract][Full Text] [Related]
16. New Medications for the Treatment of Diabetes.
Garg SK; Giordano D
Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
[No Abstract] [Full Text] [Related]
17. EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
Jørgensen NB; Pedersen J; Vaag AA
J Diabetes Complications; 2016; 30(4):753. PubMed ID: 26970674
[No Abstract] [Full Text] [Related]
18. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
Wanner C
Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
[No Abstract] [Full Text] [Related]
19. Comparison chart of SGLT2 inhibitors.
Med Lett Drugs Ther; 2017 Jan; 59(1513):e26. PubMed ID: 28118654
[No Abstract] [Full Text] [Related]
20. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
Dalama B; Biagetti B; Mesa J
Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
[No Abstract] [Full Text] [Related]
[Next] [New Search]
